Akero Therapeutics Stock Nearly Doubles — Pulling 89bio Higher — On Positive MASH Study
In This Article:
Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH obliterated expectations.
Oops, something went wrong
Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH obliterated expectations.